SAN FRANCISCO — Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic ...

SAN DIEGO — Patients with asthma exacerbations despite inhaled corticosteroids and long-acting beta 2 agonists may benefit from stepping up treatment, according to a study presented at the ...

In a placebo-controlled trial, interferon-β significantly decreased cold-induced exacerbations in patients with difficult-to-treat asthma and shortened the duration of their colds.

Asthma diagram, lungs The primary outcome was to compare dupilumab, benralizumab, and mepolizumab in patients with at least 2 pre-index exacerbations. Asthma exacerbations and systemic ...

US-based biopharmaceutical company Connect Biopharma has started a Phase II trial to assess the efficacy and safety of rademikibart in treating acute exacerbations of asthma and type II inflammation.

Host factors probably contribute to the risk of asthma inception and exacerbation, and these contributions may also vary with respect to early- versus adult-onset disease.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

Researchers identified 5 distinct clusters for disease exacerbation that went beyond disease labels for both asthma and chronic obstructive pulmonary disease (COPD).

Risk for exacerbations exists among patients with asthma regardless of control level, maintenance adherence, or disease severity.

The top asthma exacerbation triggers were weather, viral infections, and allergies, although housework and emotions were triggers linked to worse HRQoL.

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy ...